SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 59.32+2.3%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (302)5/12/2010 4:07:46 PM
From: david nordic1 Recommendation  Read Replies (4) of 507
 
Phase I data to be presented this July. 2010 ASCO poster session.

NKTR-105 is a novel, PEGylated formulation of docetaxel
(Sanofi-Aventis’s Taxotere®), developed using Nektar’s polymer
conjugate technology. This technology, according to Nektar,
can be used to optimize the bioactivity of docetaxel and other
oncolytics, and increase the sustained exposure of active drug
to tumor cells in the body.
Indeed, since docetaxel is a key component in the fight against
a wide range of cancers (commanding sales of US$2.6 billion in
2007), anything that can increase its half-life is of huge potential
benefit. Nektar hopes its technology will also solve the problem
of the unfavorable safety and tolerability profiles that can limit
the therapeutic efficacy of oncolytics.
In preclinical studies, NKTR-105 demonstrated superior antitumor
activity compared to docetaxel, with up to 2.5 times
the tumor growth delay at maximum tolerated dose. Tumor
regression was observed in a model with NKTR-105 but not
with docetaxel.
Dose-escalation, phase I trials began in February 2009,
assessing the candidate’s safety, pharmacokinetics and
antitumor activity in 30 patients with refractory solid tumors
who had failed all prior available treatments.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News